Carotid Intima-Media Thickness Is Associated with Increased Androgens in Adolescents and Young Adults with Classical Congenital Adrenal Hyperplasia

Mimi S. Kim\textsuperscript{a, d, e}, Anh Dao-Tran\textsuperscript{a}, Elana Davidowitz\textsuperscript{a}, Teresa Tseng\textsuperscript{a}, Vicente Gilsanz\textsuperscript{b, d, e}, Anna Ryabets-Lienhard\textsuperscript{a, d}, Eugene Nguyen\textsuperscript{c}, Mitchell E. Geffner\textsuperscript{a, d, e}

\textsuperscript{a}Division of Endocrinology, Diabetes, and Metabolism, \textsuperscript{b}Department of Pediatric Radiology, and \textsuperscript{c}Division of Hospital Medicine, Children's Hospital Los Angeles, \textsuperscript{d}Keck School of Medicine of the University of Southern California, and \textsuperscript{e}The Saban Research Institute, Los Angeles, Calif., USA

Introduction

Carotid intima-media thickness (CIMT) is a well-established marker of early, subclinical atherosclerotic change that corresponds to risk for coronary artery disease and stroke [1, 2]. Increased CIMT is associated with male sex, adiposity, and body mass index (BMI) in children and teens, as well as with highly sensitive C-reactive protein.
(hs-CRP) in children as young as 7 years old [3, 4]. Children with classical congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency have an increased risk for obesity and hyperandrogenism [5–8], and nonobese adolescents with CAH have demonstrated an increased prevalence of insulin resistance and increased blood pressure similar to what is seen in obese adolescents without CAH [6]. Young adults with CAH have increased CIMT, in association with decreased insulin sensitivity, compared to matched controls [9]. Current studies also suggest that polycystic ovarian syndrome (PCOS), another hyperandrogenic condition in women that is associated with cardiovascular disease risk, is also independently associated with increased CIMT [10, 11]. However, CIMT results vary in existing studies of individuals with CAH [12–14].

As the relationship between CAH and CIMT remains unclear, we set out to study CIMT in adolescents and young adults with classical CAH due to 21-hydroxylase deficiency and investigate correlations with sex, anthropometric measurements, and circulating levels of androgens, lipids, and inflammatory markers. We hypothesized that CAH subjects with bone age (BA) advancement, as a marker of excessive and/or prolonged androgen exposure, would have increased CIMT compared to CAH subjects without BA advancement. Furthermore, we hypothesized that subjects with CAH would have increased CIMT compared to matched controls without CAH and that their CIMT would have positive associations with obesity and androgen levels.

Materials and Methods

Study Participants

Individuals with classical CAH due to 21-hydroxylase deficiency and controls were recruited from the Pediatric Endocrinology and General Pediatrics clinics at Children’s Hospital Los Angeles (CHLA), respectively, and rigorously matched for age, sex, pubertal stage, ethnicity, BMI, and waist-to-height ratio (WHtR). An additional 8 unmatched, obese CAH subjects were included for within-CAH group analyses. Inclusion criteria for CAH subjects included a previous diagnosis of classical CAH due to 21-hydroxylase deficiency based on biochemical and/or genetic testing, and age ≥12 years. Controls were healthy other than being overweight or obese, and were ≥12 years old. Exclusion criteria included age <12 years, other chronic medical conditions, and inability to participate in a clinical evaluation, blood draw, and carotid artery imaging at CHLA.

Anthropometric measurements of height, weight, BMI, WHtR, and waist circumference, along with blood pressure (average of three separate readings), were obtained. BMI was categorized using Centers for Disease Control guidelines, with ≥85th percentile defined as overweight and ≥95th percentile as obese. For youth aged <18 years, prehypertension was defined as systolic blood pressure (SBP) or diastolic blood pressure (DBP) between the 90th and 94th percentile and hypertension as SBP or DBP ≥95th percentile [15]. For young adults, prehypertension was defined as SBP between 120 and 140 mm Hg or DBP between 80 and 90 mm Hg, and hypertension as SBP ≥140 mm Hg or DBP ≥90 mm Hg [16]. A waist circumference >90th percentile for age was considered increased [17]. Pertinent medical history and family history of cardiovascular disease (CVD) risk factors (early myocardial infarction, smoking, type 2 diabetes, hypertension, hyperlipidemia, and obesity) were also obtained.

The CHLA Committee on Clinical Investigations (Institutional Review Board) approved the research protocol. Patients who were 18 years old or older and parents of participating children gave written informed consent, and all minors gave assent.

Imaging

Doppler ultrasounds of the arterial wall of the left common carotid artery were performed by the same technician, with measurements taken 1 cm proximal to the carotid bifurcation using a high-resolution 15L8 MHz linear-array transducer (Acuson Sequoia 512; Siemens Medical Solutions USA, Inc., Malverne, Pa., USA), during three separate complete cardiac cycles. CIMT measurements were determined using automated, computerized edge detection software (Siemens Medical Solutions USA, Inc., 2002, v.1.0) to depict the narrowest and widest vessel diameters in the systolic and diastolic frames of each cycle, as previously described [18]. The average of three systolic and three diastolic frames was used for analysis.

A radiograph of the left hand was used to determine BA using the Greulich-Pyle method [19] and read in a blinded fashion by a single pediatric endocrinologist (M.S.K.). BA was defined as advanced when greater than the subject’s chronological age by 1 year or more. BA was obtained at the time of the study visit, or within several months of the visit if taken for clinical purposes. The individuals who had completed growth at the time of the study visit had their BA X-rays reviewed for earlier full maturity as adolescents.

Laboratory Analytes

Participants had blood drawn at our Clinical Trial Unit after an overnight (12-hour) fast and prior to routine morning medications in the CAH group. The last glucocorticoid dose was taken the evening before in all CAH patients. Fasting analytes included glucose, insulin, and lipids [total cholesterol, high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), and triglycerides] (measured by radioimmunoassay); leptin (measured by electrochemiluminescence); 17-hydroxyprogesterone (17-OHP), androstenedione, and total testosterone (measured by liquid chromatography and tandem mass spectrometry); free testosterone (calculated); and sex hormone-binding globulin (SHBG), dehydroepiandrosterone sulfate (DHEAS) and inflammatory markers (plasminogen activator inhibitor-1, antigen, hs-CRP, and homocysteine; measured by immunoassay). All analytes were measured at Quest Diagnostics Nichols Institute (San Juan Capistrano, Calif., USA). Insulin sensitivity was quantified by the homeostatic model assessment of insulin resistance [HOMA-IR = (insulin μU/ml) × (glucose mmol/l)/22.5]. Disease control was categorized based on the 17-OHP level, with CAH individuals considered suppressed if 17-OHP was <100 ng/dl, in acceptable control if between 100 and 1,200 ng/dl, in intermediate control if 1,200–5,000 ng/dl, and in poor control if >5,000 ng/dl [6].
Statistical Analysis

SPSS software (SPSS Inc., Chicago, Ill., USA) was used for all statistical analyses. Parametric and nonparametric tests were employed to test significance. Paired t tests were used to compare cases with controls, while Pearson and Spearman correlations were used to test variable relationships. All statistical assumptions were investigated before assessment. The criterion for significance was $\alpha = 0.05$ in all analyses. Power calculations were performed using G*Power 3.1 [20]. Results are shown as mean ± standard deviation.

Results

Baseline characteristics of CAH subjects and controls are shown in Table 1. Twenty adolescent and young adult subjects previously diagnosed with classical CAH were recruited along with 20 controls. The 20 CAH subjects (aged 16 ± 3.3 years, range 12.9–24.1, 50% female, and 35% obese) did not differ from controls (aged 16.5 ± 2.4 years, range 12.1–20.5, 50% female, and 30% obese) with regard to age, sex, pubertal stage, and BMI. Tanner stage ranged from IV to V for all subjects, and matching for Tanner stage by sex was done. Young adult was defined as being 18 years and older; in our cohort, there were 3 young adults with CAH, and 1 young adult without CAH.

We observed no difference between CAH subjects and controls with regard to baseline SBP, DBP, total cholesterol, and LDL. However, there were differences in triglycerides and HDL between CAH subjects and controls, with CAH having lower triglycerides and higher HDL ($p = 0.02$ and $p = 0.03$, respectively).

Including the additional 8 obese CAH subjects (n = 28), 4 young adults, aged 15.6 ± 3.2 years, range 11.8–24.1, 54% female, and 50% obese), the CAH group consisted of 71% having the salt-wasting form and 29% having the

Table 1. Clinical characteristics of adolescents and young adults with CAH due to 21-hydroxylase deficiency and controls

<table>
<thead>
<tr>
<th></th>
<th>CAH (n = 20)</th>
<th>Control (n = 20)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Females</td>
<td>10</td>
<td>10</td>
<td>N/A</td>
</tr>
<tr>
<td>Age, years</td>
<td>16 ± 3.3</td>
<td>16.5 ± 2.4</td>
<td>0.56</td>
</tr>
<tr>
<td>Weight, kg</td>
<td>65.3 ± 18.4</td>
<td>70.2 ± 23.2</td>
<td>0.47</td>
</tr>
<tr>
<td>Height, cm</td>
<td>158 ± 11.3</td>
<td>163.5 ± 9.75</td>
<td>0.11</td>
</tr>
<tr>
<td>Height SDS</td>
<td>−0.88 ± 1.19</td>
<td>−0.22 ± 1.38</td>
<td>0.12</td>
</tr>
<tr>
<td>BMI</td>
<td>26.5 ± 8.7</td>
<td>22.6 ± 8.6</td>
<td>0.93</td>
</tr>
<tr>
<td>BMI SDS</td>
<td>0.81 ± 1.17</td>
<td>0.73 ± 1.18</td>
<td>0.82</td>
</tr>
<tr>
<td>Body surface area, m²</td>
<td>1.68 ± 0.26</td>
<td>1.77 ± 0.31</td>
<td>0.30</td>
</tr>
<tr>
<td>Waist circumference, cm</td>
<td>81.5 ± 14.9</td>
<td>83.5 ± 16.5</td>
<td>0.69</td>
</tr>
<tr>
<td>Waist-to-height ratio</td>
<td>0.52 ± 0.11</td>
<td>0.51 ± 0.10</td>
<td>0.78</td>
</tr>
<tr>
<td>Heart rate, beats/min</td>
<td>74.3 ± 15.8</td>
<td>70.6 ± 9.8</td>
<td>0.42</td>
</tr>
<tr>
<td>SBP, mm Hg</td>
<td>113 ± 12.6</td>
<td>113.5 ± 10.2</td>
<td>0.89</td>
</tr>
<tr>
<td>DBP, mm Hg</td>
<td>62 ± 11.3</td>
<td>61.4 ± 8.3</td>
<td>0.86</td>
</tr>
<tr>
<td>Total cholesterol, mg/dl</td>
<td>158.7 ±32.4</td>
<td>149.9 ±28.0</td>
<td>0.36</td>
</tr>
<tr>
<td>LDL, mg/dl</td>
<td>86.3 ± 19.7</td>
<td>89.1 ± 27.3</td>
<td>0.71</td>
</tr>
<tr>
<td>Triglycerides, mg/dl</td>
<td>74.3 ± 33.9</td>
<td>119.8 ± 94.9</td>
<td>0.02</td>
</tr>
<tr>
<td>HDL, mg/dl</td>
<td>55.1 ± 12.4</td>
<td>47.0 ± 10.8</td>
<td>0.03</td>
</tr>
</tbody>
</table>

CAH group including the additional 8 obese CAH subjects (n = 28)

Glucocorticoid dose in hydrocortisone equivalents, mg/m²/day 19.5 ± 5.5
Fludrocortisone dose, mg/day 0.1 ± 0.06
17-OHP, ng/dl 5,677.3 ± 7,803.9
Androstenedione, ng/dl 198.7 ± 200.4
DHEAS (females/males), μg/dl 27.9 ± 39.9/45.2 ± 26.2
Total testosterone (females/males), ng/dl 21.4 ± 14.2/412.4 ± 225.6
Free testosterone (females/males), pg/ml 4.1 ± 3.7/63.6 ± 34.8

Figures are means ± SD unless indicated otherwise.
simple virilizing form, as determined by genotype for 90.5% of the cohort; 6 subjects with multiple heterozygous mutations identified on polymerase chain reaction analysis were classified based on clinical phenotype. Of the 28 CAH subjects, 19 were taking hydrocortisone, 8 were taking dexamethasone, and 1 was taking prednisone for their daily glucocorticoid replacement. Twenty-four of the 28 subjects were taking fludrocortisone (0.1 ± 0.06 mg/day) for mineralocorticoid replacement. As assessed by cross-sectional 17-OHP levels, 4 CAH subjects were considered suppressed, 7 were in acceptable control, 8 were in intermediate control, and 9 were in poor control.

The main finding of the study was that, within the CAH group (n = 28), mean CIMT (0.35 ± 0.05 mm) correlated positively with serum levels of 17-OHP (R = 0.48; p < 0.05; fig. 1a) and androstenedione (R = 0.46; p < 0.05; fig. 1b). Females with CAH had a lower CIMT than males with CAH (0.33 ± 0.04 vs. 0.37 ± 0.04 mm, p < 0.05; fig. 2a). Females with CAH did not have elevated androgens overall; 2 had mildly elevated androstenedione (115 and 118% of normal) and 1 of these females additionally had elevated testosterone (130% of normal). However, the subgroup of females with CAH who had an advanced BA (n = 10) also had a CIMT similar to control males (n = 10), rendering a sex-based difference in CIMT insignificant between these two groups (0.34 ± 0.04 vs. 0.35 ± 0.04 mm, p = 0.68; fig. 2b). There were also no sex-based differences in CIMT when comparing the CAH females who have advanced BA with CAH males who did not have an advanced BA (n = 6) still had a higher CIMT than the CAH females with advanced BA (0.38 ± 0.02 vs. 0.34 ± 0.04 mm, p < 0.05; fig. 2b).
There was no difference in CIMT between CAH (n = 20) and matched controls (n = 20; 0.34 ± 0.04 vs. 0.35 ± 0.04 mm, p = 0.5; fig. 3a). HDL was inversely associated with CIMT in both CAH (1.38 ± 0.31 mmol/l, r = –0.4, p < 0.05) and control (1.22 ± 0.28 mmol/l, r = –0.47, p < 0.05) groups. Otherwise, there were no correlations between CIMT and waist circumference, WHtR, BMI percentile, HOMA-IR, leptin, family history of CVD risk factors, SHBG, total cholesterol, LDL, triglycerides, triglyceride-to-HDL ratio, or inflammatory markers (plasminogen activator inhibitor-1, hs-CRP, and homocysteine) in either the CAH or control groups (data not shown). However, when including the additional 8 obese CAH subjects for a within-CAH group comparison, CIMT was significantly greater in obese CAH (n = 14) than in nonobese CAH subjects (n = 14; 0.37 ± 0.04 vs. 0.33 ± 0.04 mm, p < 0.05; fig. 3b). CIMT was also greater in obese controls (n = 6) versus nonobese controls (n = 14; 0.39 ± 0.03 vs. 0.33 ± 0.04, p < 0.05; fig. 3b). In the CAH group, CIMT did not correlate with DHEAS, total testosterone, or free testosterone. Also, there was no difference in CIMT between subjects with the salt-wasting versus simple virilizing forms of CAH. Lastly, there was no correlation between hydrocortisone equivalent dose and CIMT.

**Discussion**

Our study suggests that in adolescents and young adults with CAH, there are associations between androgens and CIMT, linking hyperandrogenism with subclinical atherosclerosis, an important emerging CVD risk factor. Known differences between the sexes exist in CIMT from puberty throughout adulthood, and ultimately, adult men have increased CVD events compared to women. The CIMT measurements in our CAH group showed the same sexual dimorphism (females: 0.33 ± 0.04 mm vs. males: 0.37 ± 0.04 mm, p < 0.05) seen in large normative studies (females: 0.38 ± 0.04 mm vs. males: 0.39 ± 0.04 mm, p < 0.05), although the ethnicity composition of our study cohorts differed [3]. Androgen excess could itself be a risk factor for CVD in women, with increased CIMT and an unfavorable overall CVD risk profile seen in hyperandrogenic women [3, 10, 11, 21]. In our CAH group, adrenal androgens, 17-OHP, and advanced BA, as a marker of substantial and prolonged androgen exposure, directly correlated with CIMT in both sexes. Laboratory analytes were measured after an overnight fast and prior to morning glucocorticoid medication administration when adrenal androgen levels are potentially at their highest. This differed from the methodology of a previous study of CIMT in adolescents with CAH that found no relationship with 17-OHP and androstenedione in which analytes were measured in blood samples drawn following the administration of morning glucocorticoid medication [12]. We also found that accounting for advanced BA in CAH females eliminated sexual dimorphism in CIMT both within CAH and between CAH versus control groups. Significant associations between androgens and CIMT have yet to be reported in adolescents and young adults with hyperandrogenism due to CAH. Our findings support the possibility that androgens may be contributing to the development of CVD risk.

Differences in CVD between men and women continue to fuel interest in the role of androgens in the development of CVD risk. It is well-established that men have earlier CVD manifestations than women in middle to late adulthood [22], but studies in men have failed to find a definitive link between higher androgen levels and CVD risk [23], with the exception of illicit androgen use for...
appearance/performance enhancement [24]. However, multiple associations exist between androgen excess and the development of an atherogenic lipid profile in hyperandrogenic women [25–27], as well as insulin resistance in adolescent girls and women [28, 29]. In postmenopausal women, the risk of hypertension correlates positively with free testosterone and DHEAS, and inversely with SHBG [30]. Androgens have been shown to have both direct and indirect effects on CVD risk, interacting with the vascular endothelium to promote inflammation and oxidative stress [31], and indirectly increasing blood pressure via actions on the kidney [30]. Possible mechanisms can be derived from rodent models, where testosterone increases the production of reactive oxygen species via activation of cytosolic NADPH-oxidase subunit p47phox, reversing the protective effects of estrogen on vascular function in postmenopausal animals [32], and reduces endothelium-dependent vasorelaxation in a PCOS model [33]. Although CVD risk in PCOS has been more extensively studied compared to CAH, the CAH model includes both sexes. Thus far, adolescents with CAH have been found to have evidence of vascular dysfunction, with reduced flow-mediated dilatation compared to controls [12]. Our study found greater CIMT in females with advanced BA, potentially demonstrating that the harmful effect of pathological hyperandrogenism on CIMT may be relevant for both males and females with CAH.

We also found that CIMT was significantly greater in obese than in nonobese adolescents and young adults, in both CAH and control groups, supporting the established theory that obesity increases the risk of developing CVD. However, our group of largely adolescent CAH subjects did not have significantly different CIMT measurements compared to controls, consistent with another study of adolescents with CAH that used similar ultrasound methods and matched their subjects for age, sex, and BMI z-score [12]. Our findings in CAH, compared to a BMI-matched cohort, suggest that individuals with classical CAH due to 21-hydroxylase deficiency may not develop subclinical atherosclerosis in adolescence. Nevertheless, since it is known that CAH confers a higher relative risk for obesity and adiposity in childhood and adolescence [5, 6, 34], it remains concerning that obese CAH subjects exhibit higher CIMT than their nonobese counterparts.

When other conventional risk factors for CVD were analyzed in our cohorts, blood pressure, total cholesterol, LDL, triglycerides, triglyceride-to-HDL ratio, and family history of CVD did not correlate with CIMT within the CAH group. Our findings that CIMT did not correlate with lipid levels (with the exception of HDL) are similar to a previous investigation in classical CAH patients [14], although the results of both studies are in contrast to associations noted between CIMT, triglycerides, and triglyceride-to-HDL ratio in a cohort that included both classical and nonclassical CAH patients [13]. However, our finding that HDL was inversely correlated with CIMT in both the CAH and control groups is consistent with normative CIMT studies in adolescents with and without obesity [35], and reports that suggest a protective effect of HDL on CVD risk [36–38] and thereby may protect against the development of atherosclerotic changes in the carotid intima media.

There are several limitations to our study. Our findings are limited by the relatively small cohort size compared to normative data samples. Additional studies with a larger sample size and longer-term follow-up would increase statistical power to compare outcomes with CIMT in adolescents and young adults with CAH, especially for subgroup analyses within the CAH cohort. However, two previous studies in CAH adolescents and young adults showed CIMT increases in CAH using comparable sample sizes of 18–19 individuals [9, 13], implying that these sample sizes have sufficient power for between-group analyses. Relative to these previously published effects, our study possesses a power of >99%. A second limitation of our study is the ethnicity of our study population, which was 70% Hispanic. The generalizability of our findings to patient populations of non-Hispanic ethnicity may be limited, given that previous studies have shown ethnicity to be an independent predictor of arterial wall thickness [39]. Conversely, the predominance of Hispanic subjects in our study could be viewed as a strength, reducing the confounding effect of interethnic variability on CIMT. Further studies are needed to determine the effect of ethnicity on CIMT in individuals with CAH. Although most CAH subjects in our study were not in acceptable hormonal control, as assessed by their early morning 17-OHP level, this degree of control is similar to that of a large cohort of CAH patients reported to have approximately 30% of patients in acceptable control [6]. Our study is also limited by its cross-sectional design, and can thus only identify associations but not determine causation.

Our study adds to the literature investigating subclinical atherosclerosis risk in adolescents and young adults with CAH, which has included varied associations between CIMT, lipids and adrenal androgens, as well as varied observations in CIMT differences between CAH sub-

Carotid Wall Thickness and Androgens in CAH

Horm Res Paediatr 2016;85:242–249
DOI: 10.1159/000444160
jects and controls [12–14]. These variations between studies may be due to differences in measures such as timing of adrenal androgen measurements in relation to the morning glucocorticoid dose, wavelength of ultrasound transducer, and study design with regard to the cohort. Our study shows that male sex, obesity, 17-OHP, androstenedione, and advanced BA positively correlate with increased CIMT, while HDL inversely correlates with CIMT. Our findings suggest that hyperandrogenism is also associated with increased CIMT after controlling for obesity, which is consistent with studies in hyperandrogenic women with PCOS [40, 41]. Particularly noteworthy is that both females and males with CAH and advanced BA, presumably reflecting prolonged hyperandrogenism, demonstrate correlations with increased CIMT. Our study suggests that hyperandrogenism in CAH is linked to increased CVD risk of subclinical atherosclerosis, independent of obesity, and that there is a potential synergistic risk of having both obesity and hyperandrogenism in patients with CAH. Given the risk for obesity, hypertension, insulin resistance, and vascular dysfunction in CAH youth, along with multiple CVD risk factors in CAH adults [6, 42, 43], further studies in CAH adolescents and young adults need to be done to assess measures of hyperandrogenism and CIMT over time. The rate of CVD events among adults with CAH is beginning to be characterized [43]. The association between CIMT progression, hormone imbalances, and medications specific to CAH, and CVD events, will be important to characterize in this at-risk cohort. Our results highlight the importance of maintaining good hormonal control, a healthy weight and active lifestyle, and monitoring lipid levels to prevent the development of CVD in patients with CAH.

Acknowledgments

We gratefully thank our patients and their families for their participation. This work was supported by Southern California Clinical and Translational Science Institute (NIH/NCCR/NCATS) Grant KL2TR000131 (to M.S.K.), Children’s Hospital Los Angeles Clinical and Translational Science Institute Clinical Trials Unit Grant 1UL1RR031986 (to M.S.K.), and The Abell Foundation (to M.E.G.). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. We also thank Norma Castaneda, Sheela Rao, Christina Reh, the Children’s Hospital Los Angeles Clinical Trials Unit, and the Children’s Hospital Los Angeles Children’s Imaging Research Program for their assistance and support.

References

Carotid Wall Thickness and Androgens in CAH

DOI: 10.1159/000444169